Pneumococcus and quinolone resistance;Neumococo y resistencia a quinolonas

Archivos de Bronconeumologia

Volumn 39, Issue 3, 2003, Pages 97-100

  Bello, S ^a,c   Torres, A ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL MUTATION; BACTERIAL TRANSMISSION; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; EDITORIAL; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PORTUGAL; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 0037367319     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13044146     Document Type: Editorial

References (36)

1. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24.
2. Schrag SJ, Beall B, Dowell SF. Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev 2000;13:588-601.
3. Oteo J, Alós JI, Gómez-Garcés JL. Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study. J Antimicrob Chemother 2001;47:215-8.
4. Aguilar L, Garcia-Rey C, Jiménez MJ. Presión antibiótica, desarrollo de resistencias en Streptococcus pneumoniae y fracaso clínico: un círculo no tan vicioso. Rev Esp Quimioter 2001;14:17-21.
5. Chen DK, McGeer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
6. Liñares J, de la Campa AG, Pallarés R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999;341:1546-8.
7. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JCS, Kisbey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
8. Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-8.
9. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001;35:687-90.
10. Ross JJ. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
11. Davies TA, Evangelista A, Pfleger S, Bush K, Sham DF, Goldschmidt R. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother 2002;46:119-24.
12. Zhanel GG, Hoban DJ, Chan CK. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
13. Ho PL, Tse WS, Tsang KWT, Kwok TK, Ng TK, VCC Cheng, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-7.
14. Schmitz FJ, Verhoef J, Milatovic D, Fluit AC. Treatment options for Streptococcus pneumoniae strains resistant to macrolides, tetracycline, quinolones, or trimethoprim/sulfamethoxazole. Eur J Microbiol Infect Dis 2001;20:827-9.
15. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklin, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002;8:594-7.
16. Schmitz FJ, Fischer A, Boss M, Mayer S, Milatovic D, Fluit AC. Quinolone-resistance mechanisms and in vitro susceptibility patterns among European isolates of Streptococcus mitis, Streptococcus sanguis and Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2001;20:219-22.
17. Tillotson GS, Zhao X, Drlica K. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
18. Low DE, de Azavedo J, Bast D. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
19. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat 2001;4:93-105.
20. Low DE, de Azavedo J, Weiss K, Mazzulli T, Kuhn M, Church D, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002;46:1295-301.
21. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000;160:1399-480.
22. Cruchaga S, Oteo J, Sáez JA, Campos J, Baquero F. Sistema Europeo de vigilancia EARSS: resistencia antibiótica en cepas invasivas de S. pneumoniae (España 2000). Enferm Infecc Microbiol Clin 2002;20(Supl 1):101.
23. Lister PD, Sanders CC. Pharmacodinamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001;47:811-8.
24. Ball P. Future of the quinolones. Semin Respir Infect 2001;16:215-24.
25. Klepser ME, Ernst EJ, Petzold R, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrob Agents Chemother 2001;45:673-8.
26. Thorburn CE, Edwards DI. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance. J Antimicrob Chemother 2001;48:15-22.
27. Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. Single and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 2001;48:365-74.
28. Boss M, Mayer S, Fischer A, Köhrer K, Scheuring S, Heisig P, et al. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes and Staphylococcus aureus. Antimicrob Agents Chemother 2001;45:938-42.
29. Dowell SF, Heffelfinger JD. Quinolones for community-acquired pneumonia. Arch Intern Med 2001;161:1681-2.
30. Hutchinson J. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
31. Wenzel RP, Edmond MB. Managing antibiotic resistance. N Engl J Med 2000;343:1961-3.
32. Sociedad Española de Quimioterapia. Evaluación del consumo de antibióticos en atención primaria de salud (1999). Disponible en: http://www.seq.es/revista/0101/short/short1.html.
33. Cars O, Mölstad S, Melander A. Variation in antibiotic use in the European Union. Lancet 2001;357:1851-3.
34. García Rey C, Aguilar L, Baquero F, on behalf of the Spanish Surveillance Group for Respiratory Pathogens. Influence of different factors on the ciprofloxacin resistance prevalence of Streptococcus pneumoniae in Spain. Results of one-year (1996-97) multicenter surveillance study. Antimicrob Agents Chemother 2000; 44:3481-2.
35. Williams JH. Fluoroquinolones for respiratory infections. Too valuable to overuse. Chest 2001;120:1771-5.
36. Camacho MT, Vicioso D, Berrón S, Jado I, Casal J, Fenoll A. Serotipos y resistencia a antibióticos de Streptococcus pneumoniae (enero 1997-2001). Enferm Infecc Microbiol Clin 2002;20(Supl 1):101.